YCYanyan Chi

Yanyan Chi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanyan Chi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Wang

    Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

    3 shared publications
  • Yan Sun

    Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

    3 shared publications
  • Zhengzheng Shan

    Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

    3 shared publications
  • Han Xu

    Department of Breast Disease Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Qingxia Fan

    Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Yana Zhang

    Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

    2 shared publications

Latest Publications

  • Open Access

    Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy

    by Jiayu Zhang, Songhang Xing, Shanshan Zhang, Yuan Hao, Xiaojie Qu, Wurihan Bao, Manwei Hao, Han Sun, Mingyuan Dong, Huiling Zhang, et al.

    Macrophages have emerged as central regulators of tissue homeostasis, inflammation, and regeneration, yet their remarkable phenotypic plasticity and functional heterogeneity pose substantial challenges for therapeutic modulation. This review provides a comprehensive synthesis of macrophage immunobiology and its translation into bioengineered material strategies for cancer immunotherapy, anti‐infective/inflammatory therapy, and tissue regeneration. We first delineate the ontogeny and functional specialization of tissue‐resident and tumor‐associated macrophage populations, the marker‐defined subpopulations revealed by single‐cell technologies, and the signaling networks that govern macrophage polarization. We further examine the complex crosstalk between macrophages and the microenvironment, encompassing interactions with tumor cells, fibroblasts, neutrophils, and T cells, as well as metabolic regulation by lactate, cAMP, exosomes, and trained immunity. Building on this mechanistic foundation, we systematically review bioengineered delivery platforms spanning nanoscale carriers, cell membrane‐coated biomimetic systems, surface‐functionalized particles, and macroscale hydrogels and scaffolds, emphasizing the bidirectional macrophage–material feedback that dictates therapeutic outcomes. Despite notable progress, challenges in macrophage heterogeneity, manufacturing scalability, and long‐term safety remain. We highlight emerging directions, including single‐cell and spatial transcriptomics‐guided design, trained immunity‐based strategies, and artificial intelligence‐driven material development, which together promise to accelerate the translation of macrophage‐targeting biomaterials from bench to bedside.

  • Open Access

    Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma

    by Yanyan Chi, Feng Wang, Yana Zhang, Zhengzheng Shan, Weili Tao, Yujin Lian, Dao Xin, Qingxia Fan, Yan Sun

    Apatinib, a highly selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), inhibits the angiogenesis of tumours. The function and mechanism of apatinib in oesophageal squamous cell carcinoma (ESCC) remain unknown. In present study, we found that the development of ESCC in patients was controlled by treatment of combination of apatinib and a chemotherapeutic drug. Moreover, apatinib efficiently promotes cell apoptosis, inhibits cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and activity of the Akt/mTOR pathway in ESCC cells. Western blot analysis showed that apatinib significantly increased vimentin protein levels, decreased Bcl2, matrix metalloproteinase 9 (MMP9), E-cadherin, p-Akt and p-mTOR protein levels in ESCC cells. Furthermore, apatinib enhanced chemosensitivity of cytotoxic drugs paclitaxel (TAX), 5-fluorouracil (5-FU) and cisplatin (DDP) by upregulating expression of vimentin protein, and downregulating expression of Bcl2, MMP9 and E-cadherin protein in vitro. Compared with single-agent groups, the combination of apatinib with each chemotherapeutic drug significantly repressed tumour growth and angiogenesis through blocking the expression of Ki67 and VEGFR-2 in vivo. Taken together, apatinib efficiently inhibits cell growth through blocking Bcl2 and Akt/mTOR pathway, and suppresses metastasis via inhibiting MMP9 and EMT in ESCC cells. Apatinib promoted antitumour effect of chemotherapeutic agents through promoting cell apoptosis and inhibiting EMT and angiogenesis in ESCC.


  • Open Access

    miR‐516a‐3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway

    by Yanyan Chi, Feng Wang, Tengfei Zhang, Han Xu, Yana Zhang, Zhengzheng Shan, Shaoxuan Wu, Qingxia Fan, Yan Sun

    MiR‐516a‐3p has been reported to play a suppressive role in several types of human tumours. However, the expression level, biological function and fundamental mechanisms of miR‐516a‐3p in breast cancer remain unclear. In the present study, we found that miR‐516a‐3p expression was down‐regulated and Pygopus2 (Pygo2) expression was up‐regulated in human breast cancer tissues and cells. Through analysing the clinicopathological characteristics, we demonstrated that low miR‐516a‐3p expression or positive Pygo2 expression was a predictor of poor prognosis for patients with breast cancer. The results of a dual luciferase reporter assay and Western blot analysis indicated that Pygo2 was a target gene of miR‐516a‐3p. Moreover, overexpression of miR‐516a‐3p inhibited cell growth, migration and invasion as well as epithelial‐mesenchymal transition (EMT) of breast cancer cells, whereas reduced miR‐516a‐3p expression promoted breast cancer cell growth, migration, invasion and EMT. Furthermore, we showed that miR‐516a‐3p suppressed cell proliferation, metastasis and EMT of breast cancer cells by inhibiting Pygo2 expression. We confirmed that miR‐516a‐3p exerted an anti‐tumour effect by inhibiting the activation of the Wnt/β‐catenin pathway. Finally, xenograft tumour models were used to show that miR‐516a‐3p inhibited breast cancer cell growth and EMT via suppressing the Pygo2/Wnt signalling pathway. Taken together, these results show that miR‐516a‐3p inhibits breast cancer cell growth, metastasis and EMT by blocking the Pygo2/ Wnt/β‐catenin pathway.


  • ZKSCAN3 promotes breast cancer cell proliferation, migration and invasion

    by Yanyan Chi, Han Xu, Feng Wang, Xiaoling Chen, Zhengzheng Shan, Yan Sun, Qingxia Fan